$0.16
(Market cap
$2,379 Mln
Recently Viewed
Clear AllMarket cap
$2,379 Mln
Revenue (TTM)
$6,216 Mln
P/E Ratio
12.7
P/B Ratio
3
Div. Yield
3.9 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$187 Mln
ROE
0.3 %
ROCE
2 %
Industry P/E
--
EV/EBITDA
8
Debt to Equity
11.7
Book Value
$2.9
EPS
$0.7
Face value
--
Shares outstanding
260,315,650
CFO
$16,175.00 Mln
EBITDA
$16,741.00 Mln
Net Profit
$12,623.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Organon & Co. (OGN)
| 85.8 | 128.1 | 48.0 | 9.2 | -18.2 | -- | -- |
|
BSE Sensex*
| -8.5 | 5.3 | -5.9 | -3.4 | 8.2 | 9.3 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Organon & Co. (OGN)
| -51.9 | 3.4 | -48.4 | -8.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Organon & Co. (OGN)
|
13.3 | 2,379.3 | 6,216.0 | 187.0 | 14.9 | 30.6 | 12.7 | 3.0 |
| 12.7 | 3,993.9 | 2,323.3 | 44.1 | 12.3 | -- | 56.9 | 105.4 | |
| 41.0 | 5,233.8 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.4 | 14.1 | |
| 185.0 | 9,512.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 107.7 | |
| 69.7 | 14,206.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.6 | 4,944.9 | 761.4 | 99.7 | 7.3 | 15 | 56.2 | 7.6 | |
| 22.2 | 11,181.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 8.1 | 5,499.1 | 7,682.7 | 438.7 | 15.9 | 7.5 | 11.7 | 1.1 | |
| 232.3 | 4,634.3 | 268.1 | 124.5 | 60.0 | 13.5 | 37.7 | 4.6 | |
| 59.2 | 3,736.3 | 391.6 | -76.6 | -19.3 | -16.4 | -- | 8.2 |
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and... internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1 Read more
CEO & Director
Mr. Kevin Ali
Executive VP & CFO
Mr. Matthew M. Walsh C.F.A.
Headquarters
Jersey City, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Organon & Co (OGN) is $13.32 (NYSE) as of 28-Apr-2026 16:17 EDT. Organon & Co (OGN) has given a return of -18.19% in the last 3 years.
The P/E ratio of Organon & Co (OGN) is 12.69 times as on 24-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
9.98
|
2.48
|
|
2024
|
4.49
|
8.21
|
|
2023
|
3.62
|
-52.86
|
|
2022
|
7.78
|
-8.00
|
|
2021
|
5.74
|
-5.14
|
The 52-week high and low of Organon & Co (OGN) are Rs 13.38 and Rs 5.69 as of 29-Apr-2026.
Organon & Co (OGN) has a market capitalisation of $ 2,379 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Organon & Co (OGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.